INJ's price is experiencing a significant downturn, falling by 70% from its highs in March. This steep decline suggests further potential losses for the Injective protocol.
The dramatic drop in the price could indicate a sustained bearish trend, which may impact investors' confidence in the Injective protocol going forward.
The article further elaborates on the potential extension of these losses amidst the current market conditions.
